{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:30:44Z","timestamp":1759969844948,"version":"build-2065373602"},"reference-count":130,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2000,4,1]],"date-time":"2000-04-01T00:00:00Z","timestamp":954547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2000,4,1]],"date-time":"2000-04-01T00:00:00Z","timestamp":954547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2000,4]]},"DOI":"10.1016\/s0378-5122(00)00108-0","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T16:41:02Z","timestamp":1027615262000},"page":"S11-S24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S2","title":["Hormone replacement therapy and breast cancer"],"prefix":"10.1016","volume":"34","author":[{"given":"Jo","family":"Marsden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0378-5122(00)00108-0_BIB1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0140-6736(01)72307-0","article-title":"On the treatment of inoperable carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases","volume":"2","author":"Beatson","year":"1896","journal-title":"Lancet"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(95)92713-1","article-title":"Breast cancer: cause and prevention","volume":"346","author":"Hulka","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB3","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1677\/erc.0.0040371","article-title":"Oestrogen, Beatson and endocrine therapy","volume":"4","author":"Howell","year":"1997","journal-title":"Endocrine Rel. Cancer"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB4","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0140-6736(96)05023-4","article-title":"Ovarian ablation in early breast cancer: overview of the randomised trials","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB5","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of randomised trials","volume":"351","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB6","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0140-6736(98)03301-7","article-title":"Tamoxifen for early breast cancer: an overview of randomised trials","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB7","unstructured":"Ejlertsen B, Dombernowsky P, Mouridsen HT et al. Comparable effect of ovarian ablation (OA) and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients (PRP). Proceedings of the (35th) Annual Meeting of the American Society of Clinical Oncology 1999;18:Abstract 248."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB8","unstructured":"Davidson N, O\u2019Neill A, Vukov A, et al. Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer: An Eastern Cooperative Oncology Group Phase III Intergroup Trial (E5188, INT-0101). Proceedings of the (35th) Annual Meeting of the American Society of Clinical Oncology 1999;18:Astract 249."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB9","doi-asserted-by":"crossref","unstructured":"Jakesz R, Hausmaninger H, Samonigg H et al. Comaprison of adjuvant therapy with tamoxifen and goserilin vs CMF in premenopausal stage I and II hormone-responsive breast cancer patients: Four year results of Austrian Breast Cancer Study Group (ABCSG) Trial 5. Proceedings of the (35th) Annual Meeting of the American Society of Clinical Oncology 1999;18:Abstract 250.","DOI":"10.1016\/S0959-8049(99)80701-1"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB10","doi-asserted-by":"crossref","unstructured":"Rutqvist LE. Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: A randomised trial by the Cancer Research Campaign (CRC) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group and the Gruppo Interdisciplinaire Valutazione Interventi in Oncologia (GIVIO). Proceedings of the (35th) Annual Meeting of the American Society of Clinical Oncology1999;18:Abstract 251.","DOI":"10.1016\/S0959-8049(99)80702-3"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB11","doi-asserted-by":"crossref","unstructured":"Fisher B, Constatino JP, Wickerham Dl et al. and other National Surgical Adjuvant Breast and Bowel Project Investigators. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371\u20131388.","DOI":"10.1093\/jnci\/90.18.1371"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB12","unstructured":"Jordan VC, Glusman JE, Eckert S et al. Raloxifene reduces incident primary breast cancer: integrated data from multi-centre, double-blind, placebo-controlled, randomised trials in postmenopausal women. Br Cancer Res Treat 1998;50:Abstract 277"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB13","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/jnci\/87.3.190","article-title":"A prospective study of endogenous estrogens and breast cancer in postmenopausal women","volume":"87","author":"Toniolo","year":"1995","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/jnci\/88.5.291","article-title":"Serum sex hormone levels after menopause and subsequent breast cancer","volume":"88","author":"Berrino","year":"1996","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/bjc.1997.398","article-title":"A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey","volume":"76","author":"Thomas","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB16","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/jnci\/90.17.1292","article-title":"Plasma sex steroid levels and risk of breast cancer in postmenopausal women","volume":"90","author":"Hankinson","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB17","doi-asserted-by":"crossref","first-page":"270","DOI":"10.7326\/0003-4819-130-4_Part_1-199902160-00004","article-title":"Elevated serum estradiol and testosterone concentrations are assocaited with a high risk fro breast cancer","volume":"130","author":"Cauley","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF01806162","article-title":"Influence of plasma oestrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer","volume":"39","author":"L\u00f8nning","year":"1996","journal-title":"Br. Cancer Res. Treat."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB19","series-title":"HRT: Your Questions Answered","first-page":"93","article-title":"Types of HRT available","author":"Whitehead","year":"1992"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB20","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/0277-5379(89)90377-5","article-title":"Endogenous oestrogens and androgens in normal and malignant endometrial and mammary tissues","volume":"25","author":"Thijssen","year":"1989","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB21","first-page":"827","article-title":"Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy","volume":"80","author":"Nachtigall","year":"1992","journal-title":"Obstet. Gynaecol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB22","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1126\/science.7618077","article-title":"Epidemiology faces its limits","volume":"269","author":"Taubes","year":"1995","journal-title":"Science"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.5694\/j.1326-5377.1988.tb99424.x","article-title":"Oestrogen therapy after the menopause: boon or bane?","volume":"148","author":"Armstrong","year":"1988","journal-title":"Med. J. Aust."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/archinte.1991.00400010089011","article-title":"Menopausal estrogen replacement therapy and breast cancer","volume":"151","author":"Dupont","year":"1991","journal-title":"Arch. Int. Med."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB25","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1001\/jama.1991.03460150089030","article-title":"A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer","volume":"265","author":"Steinberg","year":"1991","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB26","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/oxfordjournals.aje.a116043","article-title":"Invited commentary: does hormone replacement therapy cause breast cancer?","volume":"134","author":"Grady","year":"1991","journal-title":"Am. J. Epidemol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB27","first-page":"286","article-title":"Menopausal hormone replacement therapy and breast cancer: a meta-analysis","volume":"79","author":"Sillero-Arenas","year":"1992","journal-title":"Obstet. Gynaecol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB28","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S0002-9378(11)90784-4","article-title":"Hormone replacement therapy and risk of breast cancer: results from epidemiological studies","volume":"168","author":"Colditz","year":"1993","journal-title":"Am. J. Obs. Gynaecol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB29","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0140-6736(97)08233-0","article-title":"Breast cancer and hormone replacement therapy: collaborative reanalysis from 51 individual epidemiological studies","volume":"350","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB30","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/jnci\/91.17.1475","article-title":"Breast cancer after bilateral prophylactic oophorectomy in BRCA1 mutation carriers","volume":"91","author":"Rebbeck","year":"1999","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB31","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/1097-0142(19890301)63:5<948::AID-CNCR2820630527>3.0.CO;2-U","article-title":"Influence of exogenous estrogens, proliferative breast disease and other variables on breast cancer risk","volume":"63","author":"Dupont","year":"1989","journal-title":"Cancer"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB32","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/(SICI)1097-0142(19990315)85:6<1277::AID-CNCR9>3.0.CO;2-E","article-title":"Estrogen replacement therapy in women with a history of proliferative breast disease","volume":"85","author":"Dupont","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/oxfordjournals.aje.a113184","article-title":"Breast cancer incidence in women with progesterone deficiency","volume":"114","author":"Cowan","year":"1981","journal-title":"Am. J. Epidemol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1677\/erc.0.0040251","article-title":"Timing of surgery and the ovarian cycle","volume":"4","author":"Sainsbury","year":"1997","journal-title":"Endocr. Rel. Cancer"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB35","series-title":"Current Therapy in Oncology","first-page":"292","article-title":"Exogenous hormones and breast cancer","author":"Pike","year":"1993"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB36","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/bjc.1993.175","article-title":"Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism","volume":"67","author":"Catherino","year":"1993","journal-title":"Br. J. Cancer"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB37","first-page":"6539","article-title":"Estrogenic potential in oral contraceptives to stimulate human breast cancer cell proliferation","volume":"52","author":"Jeng","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/09513599509160194","article-title":"Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause","volume":"9","author":"Campagnoli","year":"1995","journal-title":"Gynecol. Endocr."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF01980939","article-title":"Progestin treatment depresses oestrogen receptor but not cathepsin D levels in needle aspirates of benign breast disease","volume":"19","author":"Maudelonde","year":"1991","journal-title":"Br. Cancer Res. Treat."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB40","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/bjc.1994.291","article-title":"Progestin use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease","volume":"70","author":"Plu-Bureau","year":"1994","journal-title":"Br. J. Cancer"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/00016348609157046","article-title":"Effects on breast tissue of exogenous estrogen and progestogens","volume":"134 (Suppl)","author":"Anderson","year":"1986","journal-title":"Acta. Obstet. Gynaecol. Scand."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB42","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1210\/edrv-11-2-266","article-title":"Progestin regulation of cellular proliferation","volume":"11","author":"Clarke","year":"1990","journal-title":"Endocrine Rev."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB43","first-page":"305","article-title":"Steroids, growth factors and cell cycle controls in breast cancer","volume":"53","author":"Musgrove","year":"1991","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB44","doi-asserted-by":"crossref","first-page":"106","DOI":"10.5694\/j.1326-5377.1994.tb127340.x","article-title":"The effect of hormone replacement therapy on prognostic indices in women with breast cancer","volume":"161","author":"Jones","year":"1994","journal-title":"Med. J. Aust."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB45","first-page":"13","article-title":"Hormonal replacement therapy and breast cancer","volume":"2","author":"Wren","year":"1995","journal-title":"Eur. J. Menopause"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB46","first-page":"64S","article-title":"Use of estrogen plus progestin is associated with greater increase in breast cancer risk than estrogen alone","volume":"147 (Suppl)","author":"Colditz","year":"1998","journal-title":"Am. J. Epidemol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB47","first-page":"253","article-title":"Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement therapy","volume":"10","author":"Persson","year":"1999","journal-title":"Cancer Causes Control"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB48","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.0.CO;2-6","article-title":"Breast cancer risk following long-term oestrogen and oestrogen\u2013progestin replacement therapy","volume":"81","author":"Magnusson","year":"1999","journal-title":"Int. J. Cancer"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB49","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1001\/jama.283.4.485","article-title":"Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk","volume":"283","author":"Schairer","year":"2000","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB50","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/jnci\/92.4.328","article-title":"Effect of hormone replacement therapy and breast cancer risk: estrogen versus estrogen plus progestin","volume":"92","author":"Ross","year":"2000","journal-title":"JNCI"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB51","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S0002-9378(89)80010-9","article-title":"Pharmacology of contraceptive steroids: a brief review","volume":"160","author":"Goldzieher","year":"1989","journal-title":"Am. J. Obstet. Gynaecol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB52","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000182172","article-title":"Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic properties","volume":"36","author":"Jung-Hoffman","year":"1991","journal-title":"Hormone Res."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB53","doi-asserted-by":"crossref","unstructured":"Greendale GA, Reboussin BA, Sie A et al. for the Postmenopausal Estrogen\/Progestin Interventions (PEPI) Investigators. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med 1999;130:262\u2013269.","DOI":"10.7326\/0003-4819-130-4_Part_1-199902160-00003"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB54","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1200\/JCO.1997.15.10.3201","article-title":"Effect of oestrogen and oestrogen\u2013progestin replacement regimens on mammographic breast parenchymal density","volume":"15","author":"Persson","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB55","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/jnci\/88.10.643","article-title":"Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography","volume":"88","author":"Laya","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB56","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/jnci\/87.21.1622","article-title":"Mammographic features and breast cancer risk: effects with time, age and menopausal status","volume":"87","author":"Byrne","year":"1995","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB57","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/80.19.1534","article-title":"Mammographic parenchymal features and breast cancer in the breast cancer detection demonstration project","volume":"130","author":"Brisson","year":"1988","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB58","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(05)62328-8","article-title":"Hormone replacement therapy and high incidence of breast cancer between mammographic screens","volume":"349","author":"Beral","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB59","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1093\/jnci\/89.21.1623","article-title":"Short-term cessation of hormone replacement therapy and improvement of mammographic specificity","volume":"89","author":"Harvey","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB60","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0009-9260(97)80053-0","article-title":"The effect of hormone replacement therapy on recall rate in the National Health Service Breast Screening Programme","volume":"52","author":"Litherland","year":"1997","journal-title":"Clin. Radiol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB61","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/archinte.1991.00400010095012","article-title":"Decreased mortality in users of oestrogen replacement therapy","volume":"151","author":"Henderson","year":"1991","journal-title":"Arch. Int. Med."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB62","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/S0140-6736(95)92632-1","article-title":"Breast cancer response to HRT withdrawal","volume":"345","author":"Powles","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB63","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/1097-0142(19950101)75:1<43::AID-CNCR2820750109>3.0.CO;2-#","article-title":"Estrogen replacement therapy withdrawal and regression of metastatic breast cancer","volume":"75","author":"Dhodapkar","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB64","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2214\/ajr.167.2.8686614","article-title":"Marked regression of a nonpalpable breast cancer after cessation of HRT","volume":"167","author":"Harvey","year":"1996","journal-title":"Am. J. Roentgneol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB65","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0029-7844(94)00324-7","article-title":"Clinical and biologic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy","volume":"85","author":"Bonnier","year":"1995","journal-title":"Obstet. Gynaecol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB66","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1136\/bmj.296.6633.1349","article-title":"Oestrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle","volume":"296","author":"Markopoulous","year":"1988","journal-title":"Br. Med. J."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB67","unstructured":"Foidart JM, Colin C, Denoo X, Desreux J, Fournier S, de Lini\u00e8res B. Influence of percutaneous administration of estradiol and progesterone on the proliferation of human breast epithelial cells. In: Calvo F, Cr\u00e9pin M, Magdelenat H, editors. Breast Cancer, Advances in Biology and Therapuetics. John Libbey Eurotext\u00a9, 1996: 329\u2013334."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB68","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1056\/NEJM199706193362501","article-title":"Postmenopausal hormone therapy and mortality","volume":"336","author":"Grodstein","year":"1997","journal-title":"NEJM"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB69","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0002-9378(84)80002-2","article-title":"Proposal to decrease the risk and improve the prognosis in breast cancer","volume":"150","author":"Gambrell","year":"1984","journal-title":"Am. J. Obstet. Gynaecol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB70","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/oxfordjournals.aje.a115008","article-title":"Postmenopausal estrogen use and mortality","volume":"128","author":"Criqui","year":"1988","journal-title":"Am. J. Epidemol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB71","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/oxfordjournals.aje.a115328","article-title":"Prognosis after breast cancer diagnosis in women exposed to oestrogen and oestrogen\u2013progestogen replacement therapy","volume":"130","author":"Berkqvist","year":"1992","journal-title":"Am. J. Epidemol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB72","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/j.1471-0528.1990.tb02494.x","article-title":"Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis","volume":"97","author":"Hunt","year":"1990","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB73","first-page":"400","article-title":"The relationship between breast cancer survival and prior postmenopausal estrogen use","volume":"80","author":"Strickland","year":"1992","journal-title":"Obstet. Gynaecol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB74","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.2105\/AJPH.85.8_Pt_1.1128","article-title":"Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women","volume":"85","author":"Folsom","year":"1995","journal-title":"Am. J. Pub. Health"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB75","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/(SICI)1097-0215(19960729)67:3<327::AID-IJC4>3.0.CO;2-T","article-title":"Cancer incidence and mortality in women receiving estrogen and estrogen\u2013progestin replacement therapy-long-term follow-up of a Swedish cohort","volume":"67","author":"Persson","year":"1996","journal-title":"Int. J. Cancer"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB76","first-page":"449","article-title":"Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States","volume":"7","author":"Willis","year":"1996","journal-title":"Cancer Causes Control"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB77","doi-asserted-by":"crossref","first-page":"973","DOI":"10.7326\/0003-4819-127-11-199712010-00004","article-title":"The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer","volume":"127","author":"Sellers","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB78","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/sj.bjc.6690543","article-title":"Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients","volume":"80","author":"Jernstr\u00f6m","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB79","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/jnci\/91.3.264","article-title":"Estrogen replacement therapy and breast cancer survival in a large screening study","volume":"91","author":"Schairer","year":"1999","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB80","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1001\/jama.281.22.2091","article-title":"Hormone replacement therapy and risk of breast cancer with a favourable histology","volume":"281","author":"Gapstur","year":"1999","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB81","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0378-5122(94)90058-2","article-title":"Do women taking hormone replacement therapy have a higher uptake of screening mammograms?","volume":"19","author":"Seeley","year":"1994","journal-title":"Maturitus"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB82","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0936-6555(05)80270-5","article-title":"The prevalence of menopausal symptoms in patients treated for breast cancer","volume":"6","author":"Canney","year":"1994","journal-title":"Clin. Oncol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB83","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.1995.13.11.2737","article-title":"Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy","volume":"13","author":"Couzi","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB84","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1002\/(SICI)1097-0142(19980501)82:9<1682::AID-CNCR14>3.0.CO;2-0","article-title":"Hot flashes in postmenopausal women treated for breast carcinoma","volume":"82","author":"Carpenter","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB85","unstructured":"Zahasky KM, Loprinzi CL, Sloan J, Novotny PJ, Quella SK. Detailed prospective data regarding tamoxifen-induced hot flashes. Proceedings of the (35th) Annual Meeting of the American Society of Clinical Oncology 1999;19:Abstract 2283."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB86","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.1999.17.8.2365","article-title":"Risk of menopause during the first year after breast cancer diagnosis","volume":"17","author":"Goodwin","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB87","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJM199408113310602","article-title":"Megestrol acetate for the prevention of hot flashes","volume":"331","author":"Loprinzi","year":"1994","journal-title":"NEJM"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB88","unstructured":"Rees CMP, Brockie JA, Suffling K, O\u2019Byrne K, Harris A, Clarke PJ. Megestrol acetate to treat vasomotor symptoms. Proceedings of the 8th International Congress on the Menopause, Sydney, Australia 3rd\u20137th Novenber 1996, Maturitas 1997;Suppl 1:Abstract 233."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB89","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/00042192-199603040-00007","article-title":"Climacteric symptoms, gonadotrophins, sex steroids and binding proteins with conjugated equine estrogen\u2013progestin and tibolone over two years","volume":"4","author":"Milner","year":"1996","journal-title":"Menopause: J. N. Am. Menopause Soc."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB90","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/(SICI)1097-0142(19980501)82:9<1789::AID-CNCR27>3.0.CO;2-#","article-title":"Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes","volume":"82","author":"Quella","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB91","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1136\/bmj.308.6927.501","article-title":"Effect of oral gamolenic acid for evening primrose oil on menopausal flushing","volume":"308","author":"Chenoy","year":"1992","journal-title":"Br. Med. J."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB92","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1200\/JCO.1998.16.2.495","article-title":"Prospective evaluation of vitamin E for hot flashes in breast cancer survivors","volume":"16","author":"Barton","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB93","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.1994.12.1.155","article-title":"Transdermal clonidine for ameliorating tamoxifen-induced hot flashes","volume":"12","author":"Goldberg","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB94","unstructured":"Quella SK, Loprinzi CL, Barton D et al. Evaluation of soy phytoestrogens for treatment of hot flashes in breast cancer survivors: an NCCTG trial. Proceedings of the (35th) Annual Meeting of the American Society of Clinical Oncology 1999;19:Abstract 2285."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB95","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1200\/JCO.1998.16.7.2377","article-title":"Pilot evaluation of venlaflexine hydrochloride for the therapy of hot flashes in cancer survivors","volume":"16","author":"Loprinzi","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB96","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/136218079900500309","article-title":"Herbal remedies as a treatment of some frequent symptoms during menopause","volume":"5","author":"Ernst","year":"1999","journal-title":"J. Br. Menopause Soc."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB97","doi-asserted-by":"crossref","unstructured":"Cheblowski RT, Collyar DE, Somerfield MR, Pfister D for the American Society of Clinical Oncology Working Group on Breast Cancer Risk Reduction Strategies. Tamoxifen and Raloxifene, J Clin Oncol 1999;17:1939\u20131955.","DOI":"10.1200\/JCO.1999.17.6.1939"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB98","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1001\/jama.1977.03270460065023","article-title":"Diethylstilbestrol: recommended dosages for different categories of breast cancer patients","volume":"237","author":"Carter","year":"1977","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB99","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/1097-0142(19900215)65:4<847::AID-CNCR2820650402>3.0.CO;2-A","article-title":"Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients","volume":"65","author":"Sutton","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB100","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1200\/JCO.1995.13.2.430","article-title":"Influence of prior and subsequent pregnancy on breast cancer prognosis","volume":"13","author":"von Scholtz","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB101","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/BF02470819","article-title":"The effect of adjuvant therapy with or without tamoxifen on the endocrine function of patients with breast cancer","volume":"20","author":"Yasamura","year":"1990","journal-title":"Jpn. J. Surg."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB102","first-page":"499","article-title":"Randomised study comparing chemotherapy with and without estrogen priming in advanced breast cancer","volume":"4","author":"Horn","year":"1994","journal-title":"Int. J. Oncol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB103","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/0959-8049(94)90413-8","article-title":"The results of modified use of chemotherapy for patients with metastatic breast cancer","volume":"30A","author":"Hug","year":"1994","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB104","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0010-7824(93)90095-O","article-title":"Pilot trial of a gonadotrophin hormone agonist with replacement hormones as a prototype to prevent breast cancer","volume":"47","author":"Spicer","year":"1993","journal-title":"Contraception"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB105","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/0277-5379(89)90372-6","article-title":"Hormone replacement therapy in women treated for breast cancer","volume":"25","author":"Stoll","year":"1989","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB106","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0002-9610(05)80848-7","article-title":"Hormone replacement therapy in previously treated breast cancer patients","volume":"165","author":"Wile","year":"1993","journal-title":"Am. J. Surg."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB107","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/0140-6736(93)92209-C","article-title":"Hormone replacement therapy in breast cancer","volume":"342","author":"DiSaia","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB108","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/0140-6736(93)91931-B","article-title":"Hormone replacement after breast cancer","volume":"342","author":"Powles","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB109","first-page":"67","article-title":"A case-controlled study of combined continuous oestrogen\u2013progestogen replacement therapy amongst women with a personal history of breast cancer","volume":"2","author":"Eden","year":"1995","journal-title":"Menopause: J. N. Am. Menopause. Soc."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB110","unstructured":"Vassilopoulou-Sellin R, Theriault R, Klein MJ. Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer. Proceedings of the (32nd) Annual Meeing of the American Society of Clinical Oncology 1996;15:Abstract 50."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB111","unstructured":"Peters GN, Jones SE. Estrogen replacement therapy in breast cancer patients: a time for change. Proceedings of the (32nd) Annual Meeting of the American Society of Clinical Oncology 1996;15:Abstract 148."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB112","unstructured":"Decker D, Cox T, Burdakin J, Jaiyesimi I, Pettinga J, Benitez P. Hormone replacement therapy (HRT) in breast cancer survivors. Proceedings of the (32nd) Annual Meeting of the American Society of Clinical Oncology 1996;15:Abstract 209."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB113","unstructured":"Bluming AZ, Waisman JR, Dosik GM et al. Hormone replacement therapy in women with previously treated primary breast cancer. Proceedings of the (35th) Annual Meeting of the American Society of Clinical Oncology 1999;18:Abstract 471."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB114","unstructured":"Espie M, Gorins A, Perret F et al. Hormone replacement therapy (HRT) in patients treated for breast cancer: analysis of a cohort of 120 patients. Proceedings of the (35th) Annual Meeting of the American Society of Clinical Oncology 1999;18:Abstract 2262."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB115","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0002-9378(99)70550-8","article-title":"Estrogen replacement therapy in women with previous breast cancer","volume":"181","author":"Natrajan","year":"1999","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB116","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1053\/ejso.1998.0617","article-title":"A case-control study of hormone replacement therapy after primary surgical breast cancer treatment","volume":"25","author":"Ur\u0161ic-Vr\u0161caj","year":"1999","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB117","doi-asserted-by":"crossref","unstructured":"Consensus Statement, Treatment of estrogen deficiency symptoms in women surviving breast cancer. J Clin Endocrin Metab 1998;83:1993\u20132000.","DOI":"10.1210\/jc.83.6.1993"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB118","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(98)85012-5","article-title":"Interim analysis of breast cancer in The Royal Marsden Hospital tamoxifen randomised chemoprevention trial","volume":"352","author":"Powles","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB119","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0140-6736(98)04394-3","article-title":"Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women","volume":"352","author":"Veronesi","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB120","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1200\/JCO.1997.15.2.840","article-title":"Clinical potential of new antoestrogens","volume":"15","author":"Gradishar","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB121","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/archinte.1991.00400090120021","article-title":"Symptoms associated with tamoxifen treatment in postmenopausal women","volume":"151","author":"Love","year":"1991","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB122","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/oxfordjournals.annonc.a010715","article-title":"The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study","volume":"7","author":"Chang","year":"1996","journal-title":"Ann. Oncol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB123","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF00689678","article-title":"The Royal Marsden Hospital chemoprevention trial","volume":"31","author":"Powles","year":"1994","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB124","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","article-title":"Effect of tamoxifen in bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women","volume":"14","author":"Powles","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB125","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1023\/A:1005999008736","article-title":"Variation in endometrial thickening in women with amenorrhoea","volume":"48","author":"Chang","year":"1998","journal-title":"Br. Cancer Res. Treat."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB126","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1200\/JCO.1999.17.5.1488","article-title":"Effect of tamoxifen on sexual functioning in patients with breast cancer","volume":"17","author":"Mortimer","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB127","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/bjc.1998.542","article-title":"Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial","volume":"78","author":"Decensi","year":"1998","journal-title":"Br. J. Cancer"},{"key":"10.1016\/S0378-5122(00)00108-0_BIB128","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00000441-199209000-00001","article-title":"Estrogen-replacement therapy in women with breast cancer: a survey of patient attitudes","volume":"304","author":"Vassilopoulou-Sellin","year":"1992","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB129","unstructured":"Ganz PA, Greendale G, Kahn B, O\u2019Leary JF. Are breast cancer survivors (BCS) willing to take hormone replacement therapy (HRT)? Proceedings of the (32nd) Annual Meeting of the American Society of Clinical Oncology 1996;15:Abstract 102."},{"key":"10.1016\/S0378-5122(00)00108-0_BIB130","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0015-0282(99)00510-5","article-title":"Are randomised trials of hormone replacement therapy in symptomatic breast cancer patients feasible?","volume":"73","author":"Marsden","year":"2000","journal-title":"Fertil. Steril."}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512200001080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512200001080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:36:24Z","timestamp":1759912584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512200001080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,4]]},"references-count":130,"alternative-id":["S0378512200001080"],"URL":"https:\/\/doi.org\/10.1016\/s0378-5122(00)00108-0","relation":{},"ISSN":["0378-5122"],"issn-type":[{"type":"print","value":"0378-5122"}],"subject":[],"published":{"date-parts":[[2000,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hormone replacement therapy and breast cancer","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0378-5122(00)00108-0","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2000 Elsevier Science Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}